Synapse - Works

Results (15763)

The hematopoietic cell transplant-co-morbidity index (HCT-CI) predicts outcomes after T cell depleted (TCD) allogeneic HCT for AML and MDS

Meeting Abstract

Ratan, R.; Ceberio, I.; Hilden, P.; Devlin, S. M.; Malloy, M. A.; Barker, J. N.; Castro-Malaspina, H.; Jakubowski, A. A.; Koehne, G.; Papadopoulos, E. B.; more...
Blood (2013)

Fulltext@MSK | Save

A phase I/II open-label multicenter study of the cyclin kinase inhibitor AT7519M alone and in combination with bortezomib in patients with previously treated multiple myeloma

Meeting Abstract

Raje, N.; Hari, P. N.; Landau, H.; Richardson, P. G.; Rosenblatt, J.; Couture, N.; Lyons, J. F.; Langford, G.; Yule, M.
Blood (2013)

Fulltext@MSK | Save

Phase II trial of the BRAF inhibitor, vemurafenib, in patients with BRAF mutant relapsed or refractory hairy cell leukemia

Meeting Abstract

Park, J. H.; Chung, S. S.; Chung, Y. R.; Won, H.; Teruya-Feldstein, J.; Berger, M.; Khawaja, T. T.; Lacouture, M. E.; Levine, R. L.; Abdel-Wahab, O.; more...
Blood (2013)

Fulltext@MSK | Save

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma

Meeting Abstract

Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
Blood (2013)

Fulltext@MSK | Save

Multiple copies of MLL is the most commonly detected cytogenetic abnormality in newly diagnosed multiple myeloma and may modify disease risk

Meeting Abstract

Landry, C.; Londono, D.; Devlin, S. M.; Lesokhin, A.; Lendvai, N.; Hassoun, H.; Chung, D. J.; Koehne, G.; Jhanwar, S. C.; Giralt, S. A.; more...
Blood (2013)

Fulltext@MSK | Save

Pilot study to evaluate the prevalence of actionable oncogenic mutations in patients with relapsed refractory multiple myeloma

Meeting Abstract

Lesokhin, A.; Gonen, M.; Redling, K.; Lendvai, N.; Hassoun, H.; Landau, H.; Chung, D. J.; Koehne, G.; Patel, M.; Brennan, K. W.; more...
Blood (2013)

Fulltext@MSK | Save

Shared care for hematologic malignancy survivors: Challenges between primary care physicians and hematologist/oncologists

Meeting Abstract

Kadkhoda, H.; Karten, C.; Van Laar, E.; Weiss, E.; Oeffinger, K. C.; Krauss, J.; Tonorezos, E. S.
Blood (2013)

Fulltext@MSK | Save

T-cell depleted allogeneic hematopoietic stem cell transplantation for patients with relapsed multiple myeloma and high-risk cytogenetics permits long-lasting remissions in the absence of graft-versus-host disease

Meeting Abstract

Koehne, G.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D. J.; Bravo, C.; Giralt, S.
Blood (2013)

Fulltext@MSK | Save

Two chemotherapy-based conditioning regimens compared to TBI-based conditioning secure consistent engraftment of T-cell depleted allogeneic HSCT, similarly low incidences of GVHD and favorable rates of disease-free survival (DFS)

Meeting Abstract

Koehne, G.; Boulad, F.; Klein, E. G.; Barker, J. N.; Castro-Malaspina, H. R.; Curran, K. J.; Giralt, S. A.; Goldberg, J. D.; Hasan, A. N.; Heller, G.; more...
Blood (2013)

Fulltext@MSK | Save

Higher than expected carrier frequency of the Dyskeratosis congenita RTEL1 p.Arg1264His recessive founder In individuals of Ashkenazi Jewish ancestry

Meeting Abstract

Jalas, C.; Fedick, A.; Ballew, B. J.; Alter, B. P.; Giri, N.; Boulton, S.; Offit, K.; Petrini, J.; Treff, N.; Savage, S. A.
Blood (2013)

Fulltext@MSK | Save